Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot–Marie–Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene
Pharmaceuticals · 21.07.2023 · 16 (7) · 1034
DOI: 10.3390/ph16071034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 21.07.2023. Verfasst von Nesrine Benslimane und 9 weiteren Autor:innen. Beteiligte Einrichtung: NeurIT UR 20218, GEIST Institute, Faculté de Médecine de Limoges, University of Limoges, F-87000 Limoges, France. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Région Nouvelle Aquitaine.
Abstract (Originalsprache)
Nonsense mutations are involved in multiple peripheral neuropathies. These mutations induce the presence of a premature termination codon (PTC) at the mRNA level. As a result, a dysfunctional or truncated protein is synthesized, or even absent linked to nonsense-mediated mRNA degradation (NMD) system activation. Readthrough molecules or NMD inhibitors could be innovative therapies in these hereditary neuropathies, particularly molecules harboring the dual activity as amlexanox. Charcot–Marie–Tooth (CMT) is the most common inherited pathology of the peripheral nervous system, affecting 1 in 2500 people worldwide. Nonsense mutations in the GDAP1 gene have been associated with a severe form of CMT, prompting us to investigate the effect of readthrough and NMD inhibitor molecules. Although not clearly defined, GDAP1 could be involved in mitochondrial functions, such as mitophagy. We focused on the homozygous c.581C>G (p.Ser194*) mutation inducing CMT2H using patient human induced pluripotent stem cell (hiPSC)-derived neuronal cells. Treatment during 20 h with 100 µM of amlexanox on this cell model stabilized GDAP1 mRNAs carrying UGA-PTC and induced a restoration of the mitochondrial morphology. These results highlight the potential of readthrough molecules associated to NMD inhibitors for the treatment of genetic alterations in CMT, opening the way for future investigations and a potential therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NeurIT UR 20218, GEIST Institute, Faculté de Médecine de Limoges, University of Limoges, F-87000 Limoges, France.
- CHU Limoges, Service de Neurologie, F-87000 Limoges, France.
- Centre Hospitalier Universitaire (CHU) Limoges, Service de Biochimie et de Génétique Moléculaire, F-87000 Limoges, France.
- CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, F-59000 Lille, France.
- Centre Hospitalo-Universitaire (CHU) Limoges, UF de Bioinformatique, F-87000 Limoges, France.
ORCID-Profile: Nesrine Benslimane, Camille Loret, Ioanna Pyromali, Pierre-Antoine Faye, Frédéric Favreau, Fabrice Lejeune, Anne-Sophie Lia
Förderung
- Agence Nationale de la Recherche
- Région Nouvelle Aquitaine
Zitieren
APA
Benslimane, N., Miressi, F., Loret, C., Richard, L., Nizou, A., Pyromali, I., Faye, P. A., Favreau, F., Lejeune, F., & Lia, A. S. (2023). Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot–Marie–Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene. Pharmaceuticals, 16(7), 1034. https://doi.org/10.3390/ph16071034
Vancouver
Benslimane N, Miressi F, Loret C, Richard L, Nizou A, Pyromali I, et al. Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot–Marie–Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene. Pharmaceuticals. 2023;16(7):1034. doi:10.3390/ph16071034
BibTeX
@article{Benslimane2023,
author = {Benslimane, Nesrine and Miressi, Federica and Loret, Camille and Richard, Laurence and Nizou, Angélique and Pyromali, Ioanna and Faye, Pierre-Antoine and Favreau, Frédéric and Lejeune, Fabrice and Lia, Anne-Sophie},
title = {Amlexanox: Readthrough Induction and Nonsense-Mediated mRNA Decay Inhibition in a Charcot–Marie–Tooth Model of hiPSCs-Derived Neuronal Cells Harboring a Nonsense Mutation in GDAP1 Gene},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {7},
pages = {1034},
doi = {10.3390/ph16071034}
}
EUVIMED